Yu Wanjia, Jiang Xueyan, Bai Tuya, Lv Xiaoli, Chang Fuhou
Department of Pharmacology of Pharmaceutical College, Inner Mongolia Medical University, Hohhot, China.
Cancer Biomark. 2014;14(6):483-92. doi: 10.3233/CBM-140427.
+936C>T polymorphism of vascular endothelial growth factor (VEGF) is one of the most investigated polymorphisms, it has been suggested that it plays a vital role in tumorigenesis. Intensive studies centering on the association between VEGF +936C>T polymorphism and lung cancer risk or lung cancer patients' overall survival were conducted in recent years, but with inconclusive and ambiguous results.
We investigated whether VEGF +936C>T polymorphism influences lung cancer risk and lung cancer patients' overall survival (OS) using pooled odds ratios (ORs) and hazard ratios (HRs) with their corresponding 95% confidence intervals (CI) under different genetic models.
A total of 12 eligible studies were included. In the overall analysis, we didn't find any statistical evidence that +936C>T polymorphism was related to the risk of lung cancer in any genetic model. However, increased lung cancer risk was detected in adenocarcinoma subgroup (OR=1.532, 95%CI: 1.016-2.312, P=0.042). For an aggregate result of survival analysis, +936C>T polymorphism was linked to an unfavorable OS (HR=2.248, 95%CI: 1.257-4.017, P=0.006) under homozygous model (TT/CC).
血管内皮生长因子（VEGF）的+936C>T多态性是研究最多的多态性之一，有人认为它在肿瘤发生中起重要作用。近年来，围绕VEGF +936C>T多态性与肺癌风险或肺癌患者总生存期之间的关联进行了大量研究，但结果尚无定论且不明确。
我们使用合并比值比（OR）和风险比（HR）及其在不同遗传模型下相应的95%置信区间（CI），研究VEGF +936C>T多态性是否影响肺癌风险和肺癌患者的总生存期（OS）。
共纳入12项符合条件的研究。在总体分析中，我们未发现任何统计学证据表明+936C>T多态性在任何遗传模型中与肺癌风险相关。然而，在腺癌亚组中检测到肺癌风险增加（OR=1.532，95%CI：1.016-2.312，P=0.042）。对于生存分析的汇总结果，在纯合模型（TT/CC）下，+936C>T多态性与不良总生存期相关（HR=2.248，95%CI：1.257-4.017，P=0.006）。
